Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pratik Multani

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Cancer Chemotherapy and Biological Response Modifiers|September 2, 2004
RituximabPratik Multani, Christine A White
Journal of the National Comprehensive Cancer Network : JNCCN|November 10, 2017
Activity of Entrectinib in a Patient With the First Reported <i>NTRK</i> Fusion in Neuroendocrine CancerDarren Sigal, Marie Tartar, Marin Xavier, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 16, 2002
Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphomaThomas E Witzig, Leo I Gordon, Fernando Cabanillas, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 25, 2016
Antitumor Activity of RXDX-105 in Multiple Cancer Types with <i>RET</i> Rearrangements or MutationsGang G Li, Romel Somwar, James Joseph, et al.
British Journal of Cancer|December 4, 2015
Novel CAD-ALK gene rearrangement is drugable by entrectinib in colorectal cancerAlessio Amatu, Alessio Somaschini, Giulio Cerea, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 3, 2017
Broadening Eligibility Criteria to Make Clinical Trials More Representative: American Society of Clinical Oncology and Friends of Cancer Research Joint Research StatementEdward S Kim, Suanna S Bruinooge, Samantha Roberts, et al.
Molecular Cancer Therapeutics|October 22, 2017
ALK Inhibitor Response in Melanomas Expressing <i>EML4-ALK</i> Fusions and Alternate <i>ALK</i> IsoformsKasey L Couts, Judson Bemis, Jacqueline A Turner, et al.
NPJ Precision Oncology|June 7, 2018
Clinical and radiographic response following targeting of BCAN-NTRK1 fusion in glioneuronal tumorChristopher Alvarez-Breckenridge, Julie J Miller, Naema Nayyar, et al.
Blood|September 3, 2013
Prostaglandin-modulated umbilical cord blood hematopoietic stem cell transplantationCorey Cutler, Pratik Multani, David Robbins, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Cancer Chemotherapy and Biological Response Modifiers|September 2, 2004
RituximabPratik Multani, Christine A White
Journal of the National Comprehensive Cancer Network : JNCCN|November 10, 2017
Activity of Entrectinib in a Patient With the First Reported <i>NTRK</i> Fusion in Neuroendocrine CancerDarren Sigal, Marie Tartar, Marin Xavier, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 16, 2002
Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphomaThomas E Witzig, Leo I Gordon, Fernando Cabanillas, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 25, 2016
Antitumor Activity of RXDX-105 in Multiple Cancer Types with <i>RET</i> Rearrangements or MutationsGang G Li, Romel Somwar, James Joseph, et al.
British Journal of Cancer|December 4, 2015
Novel CAD-ALK gene rearrangement is drugable by entrectinib in colorectal cancerAlessio Amatu, Alessio Somaschini, Giulio Cerea, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 3, 2017
Broadening Eligibility Criteria to Make Clinical Trials More Representative: American Society of Clinical Oncology and Friends of Cancer Research Joint Research StatementEdward S Kim, Suanna S Bruinooge, Samantha Roberts, et al.
Molecular Cancer Therapeutics|October 22, 2017
ALK Inhibitor Response in Melanomas Expressing <i>EML4-ALK</i> Fusions and Alternate <i>ALK</i> IsoformsKasey L Couts, Judson Bemis, Jacqueline A Turner, et al.
NPJ Precision Oncology|June 7, 2018
Clinical and radiographic response following targeting of BCAN-NTRK1 fusion in glioneuronal tumorChristopher Alvarez-Breckenridge, Julie J Miller, Naema Nayyar, et al.
Blood|September 3, 2013
Prostaglandin-modulated umbilical cord blood hematopoietic stem cell transplantationCorey Cutler, Pratik Multani, David Robbins, et al.
Pageof 1